An 18-Month Prospective Evaluation of a Novel Hyaluronic Acid Filler (YYS 720) for 3-Dimensional Nasal and Chin Augmentation.

Abstract

Hyaluronic acid (HA) fillers typically require frequent reinjections. Next-generation fillers, like the Y-phasic YVOIRE^® Y-solution (YYS) 720, require extended clinical validation to confirm their long-term performance and safety. This study evaluated 18-month clinical outcomes, safety, and satisfaction of YYS 720 for nasal and chin augmentation. In this prospective, single-arm study, 16 Korean patients received YYS 720 for the nose (n = 12) and chin (n = 7). Efficacy was evaluated through practitioner-assessed Global Aesthetic Improvement Scale (GAIS), patient-reported FACE-Q™ questionnaires, and objective 3-dimensional morphometric analysis. Safety was monitored through adverse event reporting and visual analog scale (VAS) pain scores. The GAIS responder rate was 100% through Month 12 and 84.21% at Month 18. FACE-Q scores significantly increased until Month 18 for the nose (80.67 ± 24.35, P = .0015) and Month 6 for the chin (86.00 ± 18.43, P = .0156). Three-dimensional analysis showed significant long-term improvements, with 1.73 ± 1.11 mL chin volume at Month 18 (P = .0061) and a 3.99 ± 2.81° nasofrontal angle increase at Month 12 (P = .0015) compared with baseline. The mean VAS score was low (1.69 ± 1.40). Only transient swelling and tenderness occurred in 4 patients, with no long-term delayed or serious adverse events. This pilot study provides preliminary evidence supporting the 18-month efficacy and safety of YYS 720. Given its pilot nature, these findings do not constitute claims of long-term reliability or durability, which were not formally assessed. Level of Evidence: 4 (Therapeutic).